Neogenomics (NEO) Cash from Investing Activities (2010 - 2026)

Neogenomics (NEO) has 17 years of Cash from Investing Activities data on file, last reported at -$8.3 million in Q2 2026.

• Quarterly Cash from Investing Activities rose 10.68% year-over-year to -$8.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$19.9 million (down 35.04% YoY) and the FY2025 annual result came in at -$12.3 million, down 195.96% from the prior year.
• Cash from Investing Activities fell to -$8.3 million in Q2 2026, from -$5.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $23.7 million in Q1 2023 to a low of -$9.3 million in Q2 2025.
• A 5-year average of $3.6 million and a median of -$670000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 1717.59% — and 2026, when it plunged 240.45%.
• Tracing NEO's Cash from Investing Activities over 5 years: stood at -$1.1 million in 2022, then surged by 1717.59% to $17.2 million in 2023, then plunged by 131.79% to -$5.5 million in 2024, then decreased by 15.33% to -$6.3 million in 2025, then sank by 31.94% to -$8.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$8.3 million (Q2 2026), -$5.0 million (Q1 2026), and -$6.3 million (Q4 2025), per Business Quant data.